Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors

Journal of Neuro-Oncology, 05/24/2012

The findings suggest the First–line temozolomide (TMZ) was well tolerated, and did not adversely affect the quality of life of patients with leptomeningeal metastases (LMD).

Print Article Summary